Loading...
•
Dec 31, 2020
Elanco Q4 2020 Earnings Report
Elanco's Q4 2020 results reflected the inclusion of the Bayer Animal Health business, with revenue surpassing guidance due to strong performance in U.S. Pet Health, U.S. Farm Animal, and China swine, and adjusted EPS at the high end of the range.
Key Takeaways
Elanco Animal Health reported Q4 2020 results, which included the Bayer Animal Health business acquired on August 1, 2020. Revenue reached $1,139.7 million, driven by strong performance in U.S. Pet Health, U.S. Farm Animal, and China swine. Adjusted EPS was at the high end of the guidance range, and the company increased its full-year 2021 guidance.
Elanco's fourth-quarter revenue surpassed expectations, driven by U.S. Pet Health, U.S. Farm Animal, and China swine performance.
Adjusted EPS met the high end of guidance, supported by productivity initiatives.
Innovation is progressing with eight product launches planned for 2021.
The company is executing synergies from the Bayer Animal Health acquisition.
Forward Guidance
Elanco is raising full year 2021 guidance for revenue, adjusted EBITDA, and adjusted earnings per share. Elanco is also raising full year 2021 guidance for reported EPS . Additionally, Elanco is introducing guidance for the first quarter of 2021, to provide further support to the cadence of expectations throughout the full year.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...